This study is an investigator-initiated, proof-of-concept, randomised, double-blind,
placebo-controlled, parallel-group, single-centre clinical trial investigating the body
weight loss potential of dapiglutide, a dual GLP-1R/GLP-2R agonist, administered
subcutaneously once weekly. The study will investigate the efficacy of once-weekly
subcutaneously administered of 4 mg and 6 mg dapiglutide versus placebo in 54 obese
individuals (BMI >30 kg/m2) during a 12-week treatment period.